Effect of Adding TTPB to SAPB in Breast Cancer Surgery
Launched by BEZMIALEM VAKIF UNIVERSITY · Oct 8, 2023
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of combining two types of pain relief techniques, called the Serratus Anterior Plane Block (SAPB) and the Thoracic Transversus Plane Block (TTPB), for women undergoing breast cancer surgery. The goal is to see if using both techniques together can provide better pain control after surgery compared to using just the SAPB alone. Effective pain management is important because it can help reduce the need for opioid medications, which can have side effects and are associated with other health risks.
To participate in this study, women between the ages of 18 and 75 who are scheduled for breast cancer surgery may be eligible. They should have a body mass index (BMI) between 20 and 35 and should not have any serious health issues or allergies to the medications used in the study. Participants can expect to have a combination of the two pain relief techniques applied during their surgery to help manage their post-surgery pain effectively, with the hope of improving their recovery experience. It's important for interested individuals to discuss the trial with their healthcare provider and ensure they understand what participation involves.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ASA I-II-III
- • BMI 20 to 35 kg / m2
- • Patients scheduled for breast cancer surgery procedure
- Exclusion Criteria:
- • Patients with previously known allergies to the drugs to be used in the study,
- • Infection near the puncture site,
- • Patients with previous symptoms of neurological disease (TIA, syncope, dementia, etc.)
- • Known coagulation disorders,
- • Alcohol and drug use,
- • Disorder of consciousness,
- • Opioid use equal to or greater than 60 mg oral morphine equivalent per day,
- • Patients with pre-existing neuropathic pain,
- • Liver failure, renal failure, cardiac failure
- • Morbid obesity (body mass index \[BMI\] \> 35 kg m-2)
- • Uncontrolled diabetes mellitus
- • Women during pregnancy or breastfeeding
- • Not approving the informed consent form
About Bezmialem Vakif University
Bezmialem Vakif University is a prominent academic institution based in Istanbul, Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative research that aims to improve patient outcomes and enhance therapeutic strategies. Bezmialem Vakif University is committed to adhering to rigorous ethical standards and regulatory guidelines, ensuring the integrity and reliability of its clinical trials while fostering collaboration with global research communities. Through its initiatives, the university seeks to contribute significantly to the field of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported